American Society Of Clinical Oncology

SEE SCHEDULE O:ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY, EQUITABLE PATIENT CARE.

SEE SCHEDULE O:SCIENTIFIC & MEDICAL EDUCATION:IN 2022, ASCO'S ANNUAL MEETING (THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER SCIENTIFIC AND EDUCATIONAL CLINICAL ONCOLOGY MEETING), THROUGH OVER 200 SESSIONS, REACHED AN AUDIENCE OF 34,250 PROFESSIONALS, INCLUDING OVER 14,000 PROFESSIONALS FROM 136 NON-US COUNTRIES, BOTH IN-PERSON AND ONLINE. THROUGH ASCO'S ADDITIONAL MEETINGS, THE ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, THE ASCO GENITOURINARY CANCERS SYMPOSIUM, THE ASCO QUALITY CARE SYMPOSIUM, AND THE BEST OF ASCO ANNUAL MEETING, A FURTHER 9,250 PROFESSIONALS, OVER 4,000 OF WHOM WERE FROM OUTSIDE THE UNITED STATES, BENEFITED FROM THE EDUCATION, SCIENCE, AND NETWORKING THAT ASCO PROVIDED.

EXAMPLES OF OTHER PROGRAMS - PUBLICATIONS, PUBLIC INFORMATION AND POLICY:SCIENTIFIC PUBLICATIONS: ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS AND GENERAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. ASCO PUBLISHES HIGH-QUALITY, PEER-REVIEWED SCIENTIFIC PAPERS IN ITS JOURNALS: - JOURNAL OF CLINICAL ONCOLOGY (JCO)- JCO ONCOLOGY PRACTICE (JCO OP)- JCO GLOBAL ONCOLOGY (JCO GO)- JCO CLINICAL CANCER INFORMATICS (JCO CCI)- JCO PRECISION ONCOLOGY (JCO PO)- ASCO DAILY NEWSASCO ALSO PROVIDES CONTENT AND DISTRIBUTION LISTS FOR TRADE PUBLICATIONS. WHILE NOT OWNED OR PUBLISHED BY ASCO, THE PUBLICATIONS COVER NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY.PATIENT & PUBLIC INFORMATION:ASCO PROVIDES TIMELY, CREDIBLE, AND COMPREHENSIVE CANCER INFORMATION FREE OF CHARGE THROUGH ITS AWARD-WINNING WEBSITE, CANCER.NET (WWW.CANCER.NET), MOBILE APPLICATION, AND PRINT MATERIALS. CANCER.NET, WHICH CELEBRATED ITS 20TH ANNIVERSARY IN 2022, COVERS 120+ TYPES OF CANCER AND CANCER-RELATED SYNDROMES AND EVERY ASPECT OF CANCER CARE AND SURVIVORSHIP, AS WELL AS OFFERING TIMELY AND TRUSTED CANCER INFORMATION FOR PEOPLE AFFECTED BY GLOBAL EVENTS SUCH AS COVID-19 AND THE CONFLICT IN UKRAINE. ADDITIONAL INITIATIVES INCLUDED A SOCIAL MEDIA OUTREACH CAMPAIGN FOCUSED ON MENTAL HEALTH RESOURCES FOR PATIENTS AND CAREGIVERS THAT RECEIVED OVER 3 MILLION IMPRESSIONS, A SERIES OF ARTICLES DEBUNKING COMMON CANCER-RELATED MYTHS THAT RECEIVED OVER 400,000 PAGE VIEWS, AND A CONTENT-SHARING COLLABORATION WITH THE AMERICAN CANCER SOCIETY THAT RESULTED IN OVER 38,000 PAGE VIEWS OF THE SHARED CONTENT ACROSS BOTH SITES IN THE FIRST YEAR. OVER THE COURSE OF 2022, MORE THAN 57 MILLION PAGES ON CANCER.NET WERE VIEWED BY 29 MILLION PEOPLE WORLDWIDE. CONTENT IS DEVELOPED AND REVIEWED BY AN EDITORIAL BOARD COMPOSED OF 200+ MEDICAL, SURGICAL, RADIATION, AND PEDIATRIC ONCOLOGISTS; MULTIDISCIPLINARY MEMBERS OF THE ONCOLOGY TEAM SUCH AS NURSES, PHYSICIAN ASSISTANTS, AND SOCIAL WORKERS; AS WELL AS PATIENT ADVOCATES. INFORMATION IS AVAILABLE IN ENGLISH AND SPANISH, WITH SELECT RESOURCES AVAILABLE IN 9 ADDITIONAL LANGUAGES.POLICY:ASCO WORKS TO SHAPE A WIDE RANGE OF POLICY ISSUES THAT IMPACT THE CANCER CARE DELIVERY SYSTEM AND PEOPLE WITH CANCER. THE SOCIETY'S GOAL IS TO ENSURE THAT ALL PATIENTS HAVE ACCESS TO HIGH-QUALITY, AFFORDABLE CANCER CARE AND ONCOLOGY PRACTICES HAVE THE RESOURCES NEEDED TO PROVIDE THAT CARE. KEY AREAS OF FOCUS INCLUDE QUALITY AND ACCESS TO CARE, MEDICAL INSURANCE COVERAGE ISSUES, COST, DISPARITIES, PREVENTION, SURVIVORSHIP, REIMBURSEMENT, AND SUPPORT FOR CLINICAL CANCER RESEARCH. IN 2022, ASCO DREW PUBLIC ATTENTION TO THE HARMS OF PRIOR AUTHORIZATION WITH A POLICY STATEMENT DESCRIBING THE ADVERSE IMPACT OF PRIOR AUTHORIZATION ON PATIENTS AND OFFERING SEVERAL RECOMMENDATIONS FOR ADDRESSING CONCERNS.

SEE SCHEDULE O:QUALITY OF CARE INITIATIVES - CANCERLINQ, QUALITY MEASURES, GUIDELINES AND QOPI:CANCERLINQ IS A HEALTH TECHNOLOGY PLATFORM, DEVELOPED AND IMPLEMENTED BY ASCO, THAT AGGREGATES ELECTRONIC HEALTH RECORD DATA TO IMPROVE THE QUALITY OF CARE AND HEALTH OUTCOMES FOR ALL PATIENTS WITH CANCER AND TO ADVANCE EVIDENCE-BASED RESEARCH. IN 2022, CANCERLINQ'S PRACTICE FACING QUALITY MANAGEMENT AND REPORTING PLATFORM SMARTLINQ SERVED 67 ONCOLOGY PRACTICES AND CANCER CENTERS ACROSS THE US, INCLUDING 3 THAT JOINED THE NETWORK IN 2022. SMARTLINQ WAS REFRESHED IN 2022 WITH A NEW HOMEPAGE AND FEATURES. INSIDE SMARTLINQ, A SUITE OF DASHBOARDS, REPORTS, AND QUALITY MEASURE TOOLS ENABLE PRACTICE TEAMS TO TRACK THE QUALITY OF CANCER CARE AUTOMATICALLY AND PROACTIVELY, AND THE 11 UNIQUE REPORTING DASHBOARDS THAT ARE PART OF THE CANCERLINQ INSIGHTS TOOL ASSIST ONCOLOGISTS WITH CLINICAL DECISION-MAKING AND PRACTICE INSIGHTS. ADDITIONALLY, THROUGH CANCERLINQ DISCOVERY, 10 TUMOR SITE-SPECIFIC REAL-WORLD DATASETS HAVE BEEN MADE AVAILABLE TO THE RESEARCH COMMUNITY, AND IN 2022 THESE WERE UTILIZED BY A TOTAL OF 30 CANCER RESEARCHERS ACROSS 10 ACADEMIC INSTITUTIONS. IN 2022, THERE WERE A TOTAL OF 6 MANUSCRIPTS PUBLISHED IN PEER-REVIEWED JOURNALS AND 18 ABSTRACTS ACCEPTED TO SCIENTIFIC MEETINGS THAT USED DATA FROM CANCERLINQ."QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY SELF ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES: QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICES TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. PRACTICES PARTICIPATE ANNUALLY AND OVER 300 PRATICES PARTICAPTED IN 2022.QUALITY TRAINING PROGRAM. ASCO'S QUALITY TRAINING PROGRAM IS DESIGNED TO EDUCATE AND TRAIN HEMATOLGY-ONOCOLOGY PRACTICE TEAMS, THE TECHNIQUES OF CLINICAL CARE AND OPERATIONAL PERFORMANCE QUALITY IMPROVEMENT. RECENT PARTICPANTS HAVE INCLUDED, BY INTENTIONAL RECRUITMENT, PRACTICES SERVING URBAN AND RURAL UNDERSERVED POPULATIONS ADRESSING HEALTH DISPARITY. 287 ONCOLOGY PROFESSIONALS RECEIVED TRAINING IN 2022."

SEE SCHEDULE O:RESEARCH INITIATIVES - TAPUR/CENTRA:ASCO'S CENTER FOR RESEARCH AND ANALYTICS (CENTRA) LEADS ASCO'S EFFORTS IN RESEARCH AND RELATED TO CLINICAL CANCER RESEARCH. MAJOR PROGRAMS AND PROJECTS INCLUDE: (1) THE TARGETED AGENT AND PROFILING UTILIZATION REGISTRY (TAPUR) WHICH IS A PRECISION MEDICINE BASKET TRIAL INVESTIGATING THE EFFICACY OF MORE THAN 15 DIFFERENT ANTI-CANCER TARGETED AGENTS IN PATIENTS WITH ADVANCED CANCERS AND HAS ENROLLED MORE THAN 2600 PATIENTS SINCE IT OPENED IN 2016. IN 2022, THE TAPUR TEAM SUBMITTED 7 ABSTRACTS AND 4 MANUSCRIPTS; (2) ASCO'S COVID-19 REGISTRY WHICH INCLUDES A DATABASE OF OVER 6000 PATIENTS WITH CANCER AND COVID-19 FROM 2020 TO 2022 AND RESEARCH ON THE DATABASE BY CENTRA STAFF AND MADE AVAILABLE TO EXTERNAL RESEARCHERS WITH A TOTAL OF 5 SUBMITTED MANUSCRIPTS AND 6 ABSTRACTS; (3) ASCO'S MEMBER RESEARCH SURVEY POOL, WHICH FACILITATES RESEARCH OF CANCER CARE PROVIDERS BY DISSEMINATING SURVEYS FROM MERITORIOUS SURVEY RESEARCH PROJECTS TO ASCO MEMBERS WHO HAVE AGREED TO BE A PART OF THE SURVEY POOL; (4) THE STATE OF CANCER CARE IN AMERICA PROGRAM, WHICH HAS A RESEARCH AGENDA TO ASSESS AND REPORT ON THE STATE OF AND CHANGES IN CANCER CARE IN THE US, AND (5) ASCO'S SITE SELF-ASSESSMENT TOOL AND IMPLICIT BIAS TRAINING, BOTH OF WHICH WERE DEVELOPED IN COLLABORATION WITH THE ASSOCIATION OF COMMUNITY CANCER CENTERS WITH THE OBJECTIVE OF INCREASING REPRESENTATIVE OF MINORITY ENROLLMENT ON CANCER CLINICAL TRIALS. CENTRA ALSO SUPPORTS WORKSHOPS, MEETINGS, AND RESEARCH PROJECTS WITH OTHER STAKEHOLDERS IN CANCER RESEARCH, INCLUDING THE NCI, THE FDA'S ONCOLOGY CENTER FOR EXCELLENCE, AND OTHER NON-PROFIT GROUPS, SUCH AS THE FRIENDS OF CANCER RESEARCH.